{"doi":"10.3389/fonc.2022.1015264","title":"Association of baseline self-reported fatigue with overall survival after stereotactic body radiation therapy for localized prostate cancer","abstract":"Introduction: Stereotactic Body Radiation Therapy (SBRT) has emerged as a definitive therapy for localized prostate cancer (PCa). However, more data is needed to predict patient prognosis to help guide which patients will benefit most from treatment. The FACIT-Fatigue (FACIT-F) is a well validated, widely used survey for assessing fatigue. However, the role of fatigue in predicting PCa survival has yet to be studied. Herein, we investigate the role of FACIT-F as a baseline predictor for overall survival (OS) in patients undergoing SBRT for localized PCa. Methods: A retrospective review was conducted of 1358 patients who received SBRT monotherapy between January 2008 to April 2021 at an academic, tertiary referral center. FACIT-F scores (range 0 to 52) were summed for patients who answered all 13-items on the survey. FACIT-F total scores of ≥35 represented severe fatigue. Patients receiving androgen deprivation therapy were excluded. Differences in fatigue groups were evaluated using chi-squared tests. OS rates were determined using the Kaplan-Meier method and predictors of OS were evaluated using Cox proportional hazard method. Results: Baseline full FACIT-F scores and survival data was available for 891 patients. 5-year OS was 87.6% and 95.2%, respectively, for the severely fatigued and non-fatigued groups. Chi-squared analysis of fatigue groups showed no significant difference in the following categories: D'Amico risk group, age, ethnicity, grade group, T-stage, or PSA density. Severe fatigue was associated with a significant decrease in OS (hazard ratio 2.76; 95%CI 1.55 - 4.89). The Cox proportional hazard model revealed that age and FACIT-F were both statistically significant (p <0.05). Conclusion: Baseline FACIT-F scores are significantly associated with OS. Higher FACIT-F scores, representing less fatigued patients, are associated with an overall survival benefit. These results indicate that the FACIT-F survey could serve as an additional metric for clinicians in determining prognostic factors for patients undergoing SBRT.","journal":"Frontiers in Oncology","year":2022,"id":293492,"datarank":0.16479184330021646,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"self_citation_contribution":0.16479184330021646,"citation_network_contribution":0.0,"self_endowment_contribution":0.16479184330021646,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9642,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":802679,"name":"Tamir Sholklapper","orcid":"0000-0002-2059-1966","position":1,"is_corresponding":false},{"id":600876,"name":"Anish K. Simhal","orcid":"0000-0001-7848-3565","position":2,"is_corresponding":false},{"id":325662,"name":"Alan Zwart","orcid":"0000-0001-6834-9290","position":3,"is_corresponding":false},{"id":417203,"name":"Malika Danner","orcid":null,"position":4,"is_corresponding":false},{"id":589820,"name":"Deepak Kumar","orcid":"0000-0003-0613-4942","position":5,"is_corresponding":false},{"id":416475,"name":"Nima Aghdam","orcid":"0000-0001-8078-0438","position":6,"is_corresponding":false},{"id":417205,"name":"Simeng Suy","orcid":null,"position":7,"is_corresponding":false},{"id":519181,"name":"Ryan Hankins","orcid":"0000-0001-5586-0102","position":8,"is_corresponding":false},{"id":939239,"name":"Keith Kowalczyk","orcid":"0000-0002-3081-6815","position":9,"is_corresponding":false},{"id":16593,"name":"Sean P. Collins","orcid":"0000-0002-2305-9836","position":10,"is_corresponding":false},{"id":978194,"name":"Rishabh K. Simhal","orcid":"0000-0002-7017-030X","position":0,"is_corresponding":true}],"reference_count":31,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T00:30:53.818562Z","pmid":"36620537","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}